miR-25 Promotes Melanoma Progression by regulating RNA binding motif protein 47

Jiang, Qun-Qun; Liu, Weibing

doi:10.1051/medsci/201834f111

Cited by 17 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tumor suppressor gene miR-410 is downregulated in lung cancer tissues and induced apoptosis in lung cancer cells (22). miR-25 is downregulated in melanoma cells and promoted the progression of melanoma (23). In the present study, the potential roles of miR-96 in CRC were investigated.…”

Section: Discussionmentioning

confidence: 92%

Inhibition of miR‑96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1

Xiang

Mao

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the major threats to human health worldwide. In the treatment of CRC, chemoresistance affects the efficacy of platinum-based therapies. Oxaliplatin is one of the most commonly used first-line medications for the treatment of CRC; however, chemoresistance is common among patients receiving oxaliplatin treatment, which significantly decreases its therapeutic efficacy. The present study focused on the roles of microRNA (miR)-96 in the oxaliplatin resistance of CRC cells and the underlying mechanisms. First, the expression of miR-96 was compared between CRC and adjacent tissues. Furthermore, target genes of miR-96 were predicted, and a dual-luciferase reporter assay was employed to confirm whether the candidate tropomyosin 1 (TPM1) is a direct target of miR-96. In addition, CRC cells were transfected with miR-96 inhibitor, miR-negative control, small interfering RNA (siRNA) targeting TPM1 or siRNA NC, and then treated with oxaliplatin. CCK-8 assay and flow cytometry were performed to examine the proliferation and apoptosis of the CRC cell line SW480. Next, reverse transcription-quantitative PCR and western blot analysis were performed to determine the mRNA and/or protein levels of miR-96, Bcl-2, BAX and TPM1. The results indicated that miR-96 was upregulated in CRC compared with normal adjacent tissues, while TPM1 was downregulated. The luciferase activity was reduced following transfection with miR-96 mimics and luciferase reporter plasmid containing the wild-type sequence of the 3'-untranslated region of TPM1. Furthermore, knockdown of miR-96 combined with oxaliplatin reduced the viability and induced apoptosis of CRC cells, which was further verified by decreased expression of Bcl-2 and the increased expression of TPM1 and BAX. Taken together, the downregulation of miR-96 enhanced the sensitivity of CRC cells to oxaliplatin.

show abstract

Section: Discussionmentioning

confidence: 92%

Inhibition of miR‑96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1

Xiang

Mao

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Increasing evidence has identified the aberrant expression of miRNAs (microRNAs) in melanomagenesis including Uveal melanoma (UM) [114,115]. Jiang and Liu reported that miR-25 target the RNA-binding motif protein 47 (RBM47) and activated the PI3K/Akt/mTOR signaling pathway in melanoma cells [116]. Meng et al recently demonstrated clinically that miR-138 is significantly upregulated in malignant melanoma patients by regulating the PI3K/Akt/mTOR autophagy pathway via PDK1 dependent expression [117].…”

Section: Cutaneous Cancers Associated With Dysregulation Of the Pimentioning

confidence: 99%

Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy

Chamcheu

Roy

Uddin

et al. 2019

Cells

142

122

View full text Add to dashboard Cite

The mammalian or mechanistic target of rapamycin (mTOR) and associated phosphatidyl-inositiol 3-kinase (PI3K)/protein kinase B (Akt) pathways regulate cell growth, differentiation, migration, and survival, as well as angiogenesis and metabolism. Dysregulation of these pathways is frequently associated with genetic/epigenetic alterations and predicts poor treatment outcomes in a variety of human cancers including cutaneous malignancies like melanoma and non-melanoma skin cancers. Recently, the enhanced understanding of the molecular and genetic basis of skin dysfunction in patients with skin cancers has provided a strong basis for the development of novel therapeutic strategies for these obdurate groups of skin cancers. This review summarizes recent advances in the roles of PI3K/Akt/mTOR and their targets in the development and progression of a broad spectrum of cutaneous cancers and discusses the current progress in preclinical and clinical studies for the development of PI3K/Akt/mTOR targeted therapies with nutraceuticals and synthetic small molecule inhibitors.

show abstract

“…Despite the presence of literature data on the role of miR-19b and miR-25 in melanoma cells [78][79][80] , their expression levels have not been previously analyzed in patient plasma. Therefore, for the first time, our data indicate that in metastatic melanoma patients the levels of miR-19b and miR-25 increase in stable and responding patients after one month of CPI therapy.…”

Section: Discussionmentioning

confidence: 99%

Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients

Carbone

Madonna

Capone

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Immunotherapy with checkpoint inhibitors (CPIs) strongly improved the outcome of metastatic melanoma patients. However, not all the patients respond to treatment and identification of prognostic biomarkers able to select responding patients is currently of outmost importance. Considering that development of vitiligo-like depigmentation in melanoma patients represents both an adverse event of CPIs and a favorable prognostic factor, we analyzed soluble biomarkers of vitiligo to validate them as early indicators of response to CPIs. Fifty-seven metastatic melanoma patients receiving CPIs were enrolled and divided according to the best overall response to treatment. Patient sera were evaluated at pre-treatment and after 1 and 3 months of therapy. We found that basal CD25 serum levels were higher in stable and responding patients and remained higher during the first 3 months of CPI therapy compared to non-responders. CXCL9 was absent in non-responding patients before therapy beginning. Moreover, an increase of CXCL9 levels was observed at 1 and 3 months of therapy for all patients, although higher CXCL9 amounts were present in stable and responding compared to non-responding patients. Variations in circulating immune cell subsets was also analyzed, revealing a reduced number of regulatory T lymphocytes in responding patients. Altogether, our data indicate that a pre-existing and maintained activation of the immune system could be an indication of response to CPI treatment in melanoma patients.

show abstract

miR-25 Promotes Melanoma Progression by regulating RNA binding motif protein 47

Cited by 17 publications

References 31 publications

Inhibition of miR‑96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1

Inhibition of miR‑96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1

Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy

Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients

Contact Info

Product

Resources

About